Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

You keep missing the point. Kevetrin is worth money with no clinical trials (as demonstrated by those massive pre-clinical deals I cited). With a successful phase 1 you add more value. The two patients in the phase 2 are just a little cherry on top, not the meat of the value.

Forget about the phase 2. Value Kevetrin based on being a preclinical p53 modulator that has proven to be relatively safe in a phase 1.